Hospital.Help

Liverpool – With the dual GLP-1/GIP receptor agonist tirzepatide, patients not only lose more weight than with semaglutide. They also develop type 2 diabetes less frequently. And those with existing type 2 diabetes develop fewer cardiovascular diseases, as a study in eClinicalMedicine shows (2024; DOI: 10.1016/j.eclinm.2024.102777). It is now known that obesity patients with the dual…